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The antitumor agent B-CI-cAMP (B-chloro-cyclic adenosine
monophosphate) is the most potent site-selective analogue of cAMP.
It acts primarily by selective down-regulation of regulatory sub-units of
cAMP-dependent protein kinases. This results in reversion of the
neoplastic predominance of PK-I type over PK-II type protein kinase
back to the ratio more typical to of the normal phenotype. The
differential activity of B-CI-cAMP towards protein kinase isozymes leads
to inhibition of cell growth, differentiation and neoplastic reversion of
a wide variety of cancer cell lines. Since B-CI-cAMP has been
investigated as a new potential anticancer drug with no previous
studies of its mutagenic and clastogenic effects, we have investigated
the genotoxicity of B-CI-cAMP.
Genotoxic effects were estimated by the bone marrow
micronucleus assay and the occurrence of morphological
chromosome lesions in adult mice (BALB/c strain). B-CI-cAMP was
administered intraperitoneally (i.p) in three doses, 10 mg/kg b.w.; 90
mg/kg b.w. and 160 mg/kg b.w., with saline solution as a negative
control and cyclophosphamide, a known mutagen and clastogen as
a positive control at twenty four hour intervals during a seven day
period.
Micronucleus test results showed a consistent dose-dependent
pattern. Thus, with increase of the dose (10mg/kg b.w., 90 mg/kg b.w.
and 160 mg/kg b.w.) there was an increase in the frequency of
micronuclei in polychromatic erythrocytes (4.BB ± 0.35; B.32 ± 0.57;
11.75 ± 0.37) compared to the negative control (2.04 ±0.2B). Using
chromosome aberrations as an indicator of genotoxic potential,
B-CI-cAMP in all three doses (10 mg/kg b.w.; 90 mg/kg b.w. and 160
mg/kg b.w.) produced karyotype transformation of mouse bone
marrow cells. B-CI-cAMP induced structural chromosome aberrations
as lesions (2.B7 0.14; 4,37 0.14 i 5.25 0.35), interruptions (9±0.1;
12.37±0.26 i 13.37±0,33), ring chromosomes (3.62 0.21; 2.5±0,07 i
2.5±0.07), accentrics (10±0.49; 16.5±0.45 i 1B.37±0.54) and
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Robertso~ian translocations (7.12±0.26 ;90.1 i 11.24 ±0.1B) as well
as numencal chrom.osome aberrations of the aneuploidal type (36.5 ±
0.74; 60.25±0.24 I B5.62±0.5) and polyploidy (7±0.24; 5.5±0.21 i
5.B7±0.14). These results demonstrate the genotoxic potential ofthe
investigated substance.
. Key words: Antitumor agent B-CI-cAMP; genotoxicity; apoptosis;
micronucleus test; cytogenetic in vivo test; numerical and structural
aberrations
INTRODUCTION
Preclinical investigations of 8-CI-cAMP, an analogue of cAMP, with strong
antineoplastic activity in vitro and in vivo have given us new hope for treatment of
various tumors. This is the first analogue of cAMP to be introduced to phase I
clinical trials on patients with colon and breast tumors (Tortora et aI., 1995).
Cyclic-adenosinemonophosphate (cAMP) is implicated in the regulation of
growth in normal and malignant cells (Cho-Chung et aI., 1989; Cho-Chung et aI.,
1990). This second messenger is also implicated in apoptotic cell death in
lymphoid (Mc DoneB et aI., 1993) and myeloid cells (Duprez et aI., 1993). The
primary mediator of cAMP action in eukaryotic cells is cAMP-dependent protein
kinase. There are two classes of cAMP-dependent protein kinase, designated as
type I and type II,which contain distinct Rsubunits, but share common a C subunit
(Ciardiello et aI., 1990). Differential expression of these two distinct protein kinase
isozymes, have been linked to the regulation of cell growth and differentiation
(Cho-Chung et aI., 1989). It has been shown that type I cAMP-dependent protein
kinase and/or its regulatory subunit are overexpressed in cancer cell lines and
primery tumors (Ciardiello et aI., 1993). On the other hand increased R II or type
II cAMP dependent protein kinase levels are present in normal differentiated cells
and precede the cell growth arrest by cAMP analogues. The R subunits, R I and
R II, have different sites on which cAMP analogues will bind. Depending on the
substituents on the adenine ring, cAMP analogues selectively bind to site 1 (C-2;
C-8 analogues) or site 2 (C-6 analogues). Unlike intracellular cAMP, the new class
of site-selective cAMP analogues are able to selectively discriminate between the
two cAMP binding sites present on R I and R II and to modulate the intracellular
levels of regulatory subunits at micromolar concentrations. 8-CI-cAMP, the most
potent site-selective analogue (Cho-Chung et aI., 1990) is able to down requlate
the R I subunit by inducing degradation of the protein while up-regulating R II
subunit expression at the transcription level (Rohlff et aI., 1993). This potent
modulating activity of 8-CI-cAMP has shown an inhibitory effect on the growth of
a wide variety of tumors in vivo and in vitro (Cho-Chung et al ., 1990).
On the basis of preclinical and toxicological studies of 8-CI-cAMP on animal
models (Dixit et aI., 1993) phase I clinical trials have been conducted in order to
define toxicity, maximal tolerated dose, drug plasma concentrations and immu-
nological effects. All analyses were performed on patients that were refractory to
standard treatments (Tortora et aI., 1995). The literature at present available in
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connection with cAMP and its analogues, has not provided us with one scientific
paper or study concerning their genotoxic or mutagenic potential in vivo or in vitro.
The pioneer step in genotoxicological research of cAMP analogues, as highly
potent antitumor agents, was made by Baji6 (1998) and Baji6 et at. (1998; 1999).
Since 8-CI-cAMP has been investigated as a new potential anti cancer drug
with no previous studies of its mutagenic and c1astogenc effects, we have
conducted a study to estimate the genotoxicity of 8-CI-cAMPusing different doses
in the micronucleus and cytogenetic in vivo assay.
MATERIAL AND METHODS
The genotoxic potential of 8-CI-cAMPwas estimated from micronucleus and
chromosome aberration tests on bone marrow cells of BALB/c strain mice. The
method by Schmid (1975) was used for the analysis of micronuclei (MN) in
polychromatic erythrocytes (PCE) of the mouse bone marrow Cyitogenetic
analysis was performed by the direct method of rinsing the marrow of long bones
(femur and tibia) according to Hsu and Patton (1969), as modified by Zimonji6
(1990). The investigated substance was tested at three experimental
concentrations. The lowest concentration should correspond to its level in the
environment, but, as this is a synthetic substance, the level of 10 mg/kg b.w. was
taken on the basis of postnatal growth toxicity induced by 8-CI-cAMP (Milutinovi6
et al., 1996). The median concentration was established from the maximal
tolerance dose, a dose which shows clinical manifestations of mild toxicity (loss
of weight, diarea, ataxia, somnolence) (Aardema, 1994). The high concentration
is a sublethal dose of 8-CI-cAMP, 160 mg/kg b.w. based on preliminary
toxicological investigation (acute toxicity) on BALB/c mice. Experimental designe
for both in vivo tests included three groups: positive control, negative control and
experimental groups. The experimental groups were divided into three
sub-groups based on the chosen doses of 8-CI-cAMP.
The negative control group was treated with physiological saline solution.
A known mutagen, cyclophosphamide, in a dose of 40 mg/kg b.w. was used for
the positive control group. All groups had equivalent numbers of animals per test.
Thus, for the cytogenetic test 6 animals were used per dose/group (both sexes)
and for the micronucleus test 8 animals were used per dose/group (both sexes).
The animals were kept under uniform conditions (Baji6et al., 1994), housed under
a 12/12h photoperiod at constant temperature (21 °C) with free access to standard
laboratory chow and water. Cyclophosphamide and 8-CI-cAMPwere dissolved in
physiological saline solution immediately before i.p, administration, and the
volume injected was 0.01 ml/g body weight. All animals received daily l.p.
treatments for a seven day duration.
The results were statistically analysed by suitable computer programmes
(Excel, Microstat Statistica) with the use of Student's t-test (Petz, 1981).
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The administration of 8-CI-cAMP showed an ability to induce micronuclei
(MN) in polychromatic erythrocytes (PCE) of bone marrow of BALB/c mice (Table
1; Figure 1). Statistical analysis demonstrated a statistically highly significant
difference ( p<0,001) in micronuclei induction (4.88 ± 0.35; 8.32 ± 0.57; 11.75
± 0.37) over the negative control (2.04 ± 0.28) at all three concentrations of
8-CI-cAMP (1 0 mg/kg b.w.; 90 mg/kg b.w. and 160 mg/kg b.w.). Also, these results
demonstrated a dose-response relationship between exposure to 8-CI-cAMP and
the frequency of MN in PCE. Even though tis dose-response relationship indicates
8-CI-cAMP genotoxicity, we must not exclude the possibility of genotoxicity
decrease (or elimination) by reducing the dose and retaining the anti-neoplastic
effect of our investigated substance ( Baji6, 1998; Baji6 et aI., 1998; 1999).
Table 1. Frequency of polychromatic erythrocytes (PCE) with micronuclei in bone marrow cells of
control and experimental groups of strain BALB/c mice treated with increasing doses of
8-CI-cAMP
--_._-_..,-_._--_._--_._._,---~._----._.._~--_.__.
Cycles Control 10 mg/kg b.w. 90 mg/kg b.w. 160 mg/kg b.w.
cyclophosphamide
repeated 40 mg/kg b.w.
-- .-----_ ..,.,. ----_. ._---_._-
2.25 4.5 7.7 12.2 22.5
2 2 4.7 8 11.75 21.5
3 2.37 5.12 9.5 11.87 21.7
4 1.87 4.62 8 11 22.1
5 2.25 4.62 8.12 11.5 20.8
6 1.47 5.37 8.62 11.75 23
7 2 5.37 8.62 12.12 21.5
8 2.12 4.75 8 11.75 22.1
--~~--_.
X ± SO 2.04±0.28 4.88±0.35 8.32±O.57 11.74±0.37 21.86±0.71_.__ ..•._~~----""
Cyclophosphamide, an antitumor agent, used in treatment for a variety of
tumors, is also employed as a positive control in a number of genotoxicological
tests because of its known c1astogenicand mutagenic features (Anderson et aI.,
1995). Comparing the frequency of MN in PCE at the 160 mg/kg b.w. dose of
8-CI-cAMP ( 11.75 ± 0.37) and of cyclophosphamide at its therapeutic dose of
40 mg/kg b.w. (22.1 ± 0.71), we noticed that cyclophosphamide is two times more
potent as an inducor of micronuclei than 8-CI-cAMP.The same result can be more
clearly presented as a genotoxic effect of 8-CI-cAMPin relationship to our positive
control. Namely, if the frequency of MN (21.9 ± 0.71) in PCE induced by
cyclophosphamide (40 mg/kg b.w.) is taken as 100% (Table 1), then for the
experimental group receiving 160 mg/kg b.w. of 8-CI-cAMP (11.74 ± 0.37) there
was a 52.9% level of genotoxicity, at 90 mg/kg b.w. (8.32 ± 0.57) 37.6% and for
10 mg/kg b.w. (4.88 ± 0.35) 21.4%. These values demonstrate that 8-CI-cAMP
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Figure 1. Frequency of micronuclei inpolychromatic erythrocytes in
mouse bonemarrow cells of control groups andexperimental groups
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Figure 2. Micronuclei in polychromatic erythrocytes of BALB/c mice induced by 8-CI-cAMP in the dose
of 90 mg/kg b.w.
Figure 3. Micronuclei in polychromatic erythrocytes of BALB/c mice induced by 8-CI-cAMP in the dose
of 160 mg/kg b.w.
at 10 mg/kg b.w. is five times less potent in inducing MN in peE than cyclophos-
phamide in its therapeutic dose range (40 mg/kg b.w.). The possibility of using
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Figure 4. Percentage values of cytogenetic parameters in mouse bone
35 marrow cells of control groups and experimental groups treatedwith
increasing doses of 8-CI-cAMP
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10 mg/kg b.w. 90 mg/kg b.w. 160 mg/kg b.w.
Cytogenetic control cyclophosphamide 8-CI-cAMP 8-CI-cAMP 8-CI-cAMP90
parameters 40mg/kg b.w.
X±SO % X±SO % X ±SO % X± SO % X±SO %
Polyploidy 0.50±0.05 0.08 013.30±0.37 02.22 00.70±0.24 01.16 005.50±0.21 00.91 005.87±0.14 00.97
Aneuploidy 3.25±0.15 0.54 102.56±0.78 17.10 36.50±0.74 06.08 060.25±0.24 10.04 085.62±0.50 14.20
Lesions 1.00±0.08 0.16 031.39±0.52 05.22 02.87±0.14 00.47 004.37±0.14 00.72 005.25±0.35 00.87
Interruptions 1.12±0.07 0.18 016.20±0.38 02.70 00.90±0.D1 01.50 012.37±0.26 02.06 013.37±0.33 02.22
Accentrics 0.37±0.07 0.61 005.70±0.03 00.95 10.00±0.49 01.66 016.50±0.45 02.75 018.37±0.54 03.06
Ring hromosomes O.OO±O.OO 0.00 002.80±0.02 00.47 03.62±0.21 00.60 002.50±0.07 00.41 002.50±0.07 00.41
Robertsonian
0.70±0.01 0.13 014.~7±0.41 02.35 07.12±0.26 01.18 000.90±0.10 01.50 011.24±0.18 01.87translocations
Overall Cytogenetic
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lower doses to decrease or even eliminate the genotoxic effect of 8-CI-cAMP is
important for assessment of the therapeutic risk. Almost all anticancer drugs used
today have the potential to induce secondary tumors after initial treatment (Ped-
ersen et aI., 1988; Pedersen-Bjergaard and Philip., 1989), so the possibility of
reducing the genotoxicity of 8-CI-cAMPwhile it decreases the expression of c-myc
and ras oncogenes in various cancer cells in vitro and in vivo (Cho-Chung, 1990)
may give a therapeutic benefit of 8-CI-cAMP over many known anticancer drugs.
However when extrapolating any risk assessment from mice to humans we have
to stress the importance of interspecies variability, that is, the difference between
species of enzymatic systems which are responsible for metabolic activation,
distribution and elimination of the investigated substance (Tortora et aI., 1995;
Rusov et aI., 1996).
Figure 5. Aberrant karyotype with lesions and accentrics in bone marrow cells of BALB/c mice treated
with 8-CI-cAMP in the dose of 160 mg/kg b.w.
It was established by cytogenetic analysis that during a seven day (i.p.)
treatment with increasing doses of 8-CI-cAMP (10 mgjkg b.w.; 90 mgjkg b.w. and
160 mgjkg b.w.). there was an increase of frequency of numerical and structural
chromosome aberrations in mouse bone marrow cells over negative control.
Numerical aberrations of the aneuploidal and polyploidal type are the
consequence of abnormal segregation of chromosomes during cell division.
Abnormal segregation can arise by action of the investigated substance on
kinetochor proteins which affect the centromeric region or mitotic spindle, so the
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chromosomes lag due to spindle dysfunction and consequently a change in
chromosome number occurs during the cell cycle which is exhibited as numerical
chromosome aberrations (Legator et aL,1994; Soldatovic et al., 1994; Stanimi-
rovic.,1995; Markovic, 1996; Stanirnirovlc et al., 1997; Bajic, 1998; Stanimlrovic et
al., 1998; Markovic,1999). A relatively high frequency of aneuploidy and polyploidy
was noticed in the bone marrow cells of animals treated with in all three doses of
8-CI-cAMP.Thus the dose of 10 mg/kg b.w. induced aneuploidy at a level of 6.08%,
polyploidy at 0.93%; 90 mg/kg b.w. led to 10.04% aneuploidy and 0.93%
polyploidy while 160 mg/kg b.w. gave 14.2% aneuploidy and 0.97%. polyploidy
compared with 17.9% aneuploidy and 2.22% polyploidy for the positive control
(Table 2; Fig. 4). As only the dose of 10 m~/kg b.w. of 8-CI-cAMP can be
extrapolated to the therapeutic dose range used for humans (Tortora et al., 1995),
we can note that 8-CI-cAMP is almost three times less potent in induction of
aneuploidy and polyploidy than cyclophosphamide in its therapeutic dose range.
8-CI-cAMP showed the ability of inducing the following structural chromo-
some aberrations: lesions, interruptions, ring chromosomes, accentrics and
Robertsonian translocations. Structural aberrations of the lesion and interruption
type can be a sensitive and accurate parameter in estimating genotoxicity (Broger
et al., 1982). The progressive increase in both types of lesion in the experimental
groups and levels found in the positive control group (Table 2.)indicate their
relative potency in inducinq these lesions (Bajic, 1998). Also, all investigated
doses of 8-CI-cAMP induced chromosome changes of the accentric, ring chro-
mosome and Robertson translocation type in mouse bone marrow cells (Table 2:
Fig 4). Thus, highly significant differences were found in the overall percentage of
cytogenetic changes in cells of the negative control group (1.17%) and experi-
mental groups treated with three different doses of 8-CI-cAMP 12,68%, 18.41 %
and 23.7% respectively. Highly significant differences (p<0.001) were also ob-
served between all experimental groups and cyclophosphamide. Even though a
high dose regime is required for evaluating potential genotoxic effects of any
substance (Aardema,1994), our doses (90 mg/kg b.w. and 160 mg/kg b.w.) used
in vivo can result in pathologies that would be eliminated in lower dose ranges.
Therefore it can be said that high dose regimes acted saturably on the elimination,
metabolism and repetitive mechanisms (Crouch et al., 1979).
For years it has been known that cytotoxic effects of chemotherapeutic
drugs are explained as the conseqence chromosome and chromatid damage
(Soldatovic et aL, 1994; Stanimirovic.,1995; Markovic, 1996; Stanirnirovic et al.,
1997; Bajic, 1998; Stanlmirovic et al., 1998; Markovic,1999), but in recent years
it has emerged that cytotoxic effects of chemotherapeutic agents can result from
the programmed cell death apoptosos (Corcoran, et al., 1994; Boe et al., 1995).
As 8-CI-cAMP and its active metabolite 8-CI adenosine are strong inducors of
apoptosis, the relationship between genotoxic effects of cytotoxic drugs and their
apoptotic potential, that is the portion of 8-CI-cAMP genotoxicity engaged in the
induction of apoptosis should be evaluated. The early phase of apoptosis starts
with chromosome fragmentation. Three types of chromosome fragmentation can
be distinguished: intranucleosomal cleavage of DNA; degradation of DNAto long
fragments 50-300 kb in length and single-strand breaks (SSB) of DNA (Marini et
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aI., 1996). The role of SSB in the process of apoptosis is still an open question,
that is, can SSB be an early signal for apoptotic induction.
The results of our investigation have shown that in the overall picture of
registered changes on chromosomes, the highest percentage of aberrations are
of the lesion, interruption and accentrictype (figure 5). Ifwe correlate these results
with the inductive capability of 8-CI-cAMPto increase the frequency of MN in PCE
and the 8-CI-cAMP apoptotic potential, then we can pose a question: Is the
genotoxic effect of 8-CI-cAMP a primary signal for apoptotic induction or is the
induction of apoptosis an independent process? Our results strongly suggest that
there is a correlation of 8-CI-cAMP genotoxicity and its apoptotic potential, which
will have great importance for the development and use of 8-CI-cAMP as an
anticancer agent. It is also important to stress that correlative relationships
between genotoxicity and apoptosis will open new strategies forthe use of various
cytotoxic drugs by modulating the process of PCD in tumors that are refractory to
previous treatments ( Baji6, 1998).
The experimental results demonstrate a correlation between 8-CI-cAMP
cytotoxicity and genotoxicity. One of the possible reasons is that the plateau of
overall cytogenetic changes already exists at the MTD dose level (90mg/kg b.w.)
where animals clinically express signs of mild toxicity. However, is the action of
8-CI-cAMP direct or indirect, that is, are changes on chromosomes and the
induction of MN a consequence of its active metabolite 8-CI-adenosine, or both,
is a question to be answered (Cornelis et aI., 1992). The results from other
preclinical investigations of 8-CI-cAMP demonstrate a complicated action of
8-CI-cAMP in various tumor cell lines in vitro and in vivo (Cummings et aI., 1996).
Our results demonstrate indisputable evidence of the genotoxic potential of
8-CI-cAMP on bone marrow cells of BALB/c mice strain. However, correlation
between dose-response and the existence of inter and intra-species genetic
variability with regard to the metabolism of 8-CI-cAMP (Tortora et aI., 1995; Baji6,
1998) does not let us extrapolate any conclusion about assessment the carcino-
genic and mutagenic risk of 8-CI-cAMP in humans 8-CI-cAMP is the first analogue
to be evaluated in phase I clinical trials on patients with colon and breast tumors.
The results of our investigation, suggest novel molecular-biological in vitro
genotoxicological studies, especially in relation to apoptosis in order to evaluate
the overall genotoxic risk of 8-CI-cAMP treatment.
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ISPITIVANJE GENOTOKSICNOSTIB-CI-cAMP U OVA IN VIVO TESTA NA MISEVIMA SOJA
BALB/c
V. BAJIC, Z. STANIMIROVICi BILJANA MARKOVIC
SADRZAJ
Antitumorski preparat 8-CI-cAMP (s-htoro-clkltcnt adenozin monofosfat) je
najpotentniji analog AMP koji deluje primarno na modulaciju cAMP - zavisne
protein kinaze dovodeCi do inhibicije regulatornih subjedinica. Rezultat takvog
dejstva je smanjenje dominantnog tlpa PK-Iprotein kinaze u kanceroznim 6elijama
nad drugim tipom PK-II protein kinaze, u odnosu na medusobni nivo PK-I I PK-II
koji se nalaze u normalnim 6elijama. Ciklicni 8-CI-AMPje analog koji irna izuzetnu
anti-neoplasticnu aktivnost sa efektom restauracije, diferencijacije i reverzne
transformacije kanceroznih celija rnisa i coveka, Sa stanovista mogu6eg mu-
tagenog i qenotoksicnoq efekta 8-CI-cAMP nije dovoljno istra'en. Zato je i cilj ovog
rada bio da se primenom citoqenetlckoq i mikronukleus testa, na 6elijama kostne
sr'i rnisa BALB/c soja, ispita qenotoksicni efekat 8-CI-cAMP u tri dozna re'ima (10
mg/kg t.m; 90 mg/kg t.m. i 160 mg/kg t.m.). Pored eksperimentalnih grupa
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zivotinja u eksperimentu su uspostavljene i negativna kontrola koju su clnile
jedinke tretirane sa fiziolosktrn rastvorom, kao i pozitivna kontrola zivotinja koje
su tretirane sa poznatim klastogenom i mutagenom-ciklofosfamidom u dozi od
40 mg/kg t.m. Rezultati ispitivanja pokazuju konzistetni dozno-zavisni obrazac
primenom mikronukleus testa. Sa rastom doze (10 mg/kg t.m ; 90 mg/kg t.m. i
160 mg/kg t.m.) raste i broj mikronukleusa u polihromatofilnim eritrocitima (4,88
±0,35; 8,32±0,57; 11,75±0,37) u odnosu na kontrolnu grupu (2,04±0,28). Tes-
tirane rastuce doze 8-CI-cAMP u citoqenetlckorn testu in vivo pokazuju sposob-
nost transformacije kariotipa celija kostne sr'i BALB/c miseva u vidu strukturnih
hromozomskih aberacija tipa lezija (2,87±0,14; 4,37±0,14; 5,25±0,35), prekida
(90,1; 12,37±0,26; 13,37±0,33), ring hromozoma (3,62±0,21; 2,5±0,07;
2,5±0,07), acentrika (100,49; 16,5±0,45; 18,37±0,54) i Robersonovih
translokacija (7,12±0,26; 90,1; 11,24±0,18) i numerickih hromozomskih aber-
acija tipa aneuploidija (36,5±0,74; 60,25±0,24; 85,62±0,5) i poliploidija (70,24;
5,5±0,21; 5,87±0,14) sto ukazuje na postojanje qenotoksicnoq potencijala ispi-
tivane supstance.
